HBS (Human BioSystems) secures $5 million equity credit line:
This article was originally published in Clinica
Human BioSystems (HBS), a developer of biological preservation systems for blood platelets and donor organs, is to receive a maximum of $5m in common stock purchases over the next three years from Dutchess Private Equities Fund. According to Harry Masuda, HBS' president and CEO, the funding will allow the completion of its human infusion studies carried out with its blood platelet preservation solution and, eventually, with its donor organ preservation system. The Palo Alto, California company estimates the market for its products to exceed $300m in 2004.
You may also be interested in...
House and Senate Democrats sponsor legislation to authorize FTC enforcement against sales of "consumer goods and services at an unconscionably excessive price during the" COVID-19 pandemic. "It’s outrageous that some companies and individuals are taking advantage of consumers by price-gouging," says Energy and Commerce Committee Chairman Frank Pallone.
Robert Califf, a former FDA commissioner turned Verily Life Sciences exec, is just one of the voice predicting a long-term impact on clinical trial processes from the COVID-19 outbreak.
A US National Academies meeting on digital health technology showcased the communication gap between regulators and tech developers when it comes to important concepts like “digital biomarkers.”